OPDIVO Safety Information
OPDIVO Product Monograph
Request a Rep
Français

Home
Efficacy
CheckMate-76K Study Design
Dosing
Safety Profile

Log Out

Menu

Home

Efficacy

CheckMate-76K Study Design

Dosing

Safety Profile

Home

Efficacy

CheckMate-76K Study Design

Dosing

Safety Profile

Home

Efficacy

CheckMate-76K Study Design

Dosing

Safety Profile

Home

Efficacy

CheckMate-76K Study Design

Dosing

Safety Profile

Home

Efficacy

CheckMate-76K Study Design

Dosing

Safety Profile

2 Dosing Options

Dosing Graph

Adapted from Product Monograph¹

IV: intravenous; Q2W: every 2 weeks; Q4W: every 4 weeks.

References

Privacy Policy Legal Notice

innovativemeds

©2024 Bristol-Myers Squibb Company 1506-CA-2400017E

OPDIVO and the OPDIVO logo are registered trademarks of Bristol-Myers Squibb Company used under license by Bristol-Myers Squibb Canada.